Effects of switching to rituximab from ongoing first-line injectable therapies in patients with relapsing-remitting multiple sclerosis
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Jun 2016 New trial record
- 17 Jun 2016 Primary endpoint of change in mean CSF levels of NFL before and 1 year after rituximab treatment has been met, according to results published in the Neurology.
- 17 Jun 2016 Primary endpoint of difference in mean number of Gd+ MRI lesions per patient calculated on the run-in examinations at month -3 and 0 compared with the examinations performed at months 3 and 6 has been met, according to results published in the Neurology.